Compare SII & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SII | IDYA |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | SII | IDYA |
|---|---|---|
| Price | $122.67 | $30.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $132.00 | $49.67 |
| AVG Volume (30 Days) | 315.1K | ★ 829.6K |
| Earning Date | 02-19-2026 | 02-13-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $216,267,000.00 | $214,834,000.00 |
| Revenue This Year | $27.96 | $2,688.43 |
| Revenue Next Year | $4.65 | N/A |
| P/E Ratio | $63.26 | ★ N/A |
| Revenue Growth | 22.38 | ★ 5377.66 |
| 52 Week Low | $39.33 | $13.45 |
| 52 Week High | $143.00 | $39.28 |
| Indicator | SII | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 35.03 |
| Support Level | $117.07 | $31.81 |
| Resistance Level | $125.30 | $33.63 |
| Average True Range (ATR) | 6.39 | 1.58 |
| MACD | -1.50 | -0.32 |
| Stochastic Oscillator | 30.61 | 12.65 |
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.